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Abstract
Summary Changes of the bone formation marker PINP cor-
related positively with improvements in vertebral strength in
men with glucocorticoid-induced osteoporosis (GIO) who
received 18-month treatment with teriparatide, but not with
risedronate. These results support the use of PINP as a
surrogate marker of bone strength in GIO patients treated
with teriparatide.
Introduction To investigate the correlations between bio-
chemical markers of bone turnover and vertebral
strength estimated by finite element analysis (FEA) in
men with GIO.
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Methods A total of 92 men with GIO were included in an
18-month, randomized, open-label trial of teriparatide
(20 μg/day, n=45) and risedronate (35 mg/week, n=47).
High-resolution quantitative computed tomography images
of the 12th thoracic vertebra obtained at baseline, 6 and 18
months were converted into digital nonlinear FE models and
subjected to anterior bending, axial compression and tor-
sion. Stiffness and strength were computed for each model
and loading mode. Serum biochemical markers of bone
formation (amino-terminal-propeptide of type I collagen
[PINP]) and bone resorption (type I collagen cross-linked
C-telopeptide degradation fragments [CTx]) were measured
at baseline, 3 months, 6 months and 18 months. A mixed-
model of repeated measures analysed changes from baseline
and between-group differences. Spearman correlations
assessed the relationship between changes from baseline of
bone markers with FEA variables.
Results PINP and CTx levels increased in the teriparatide
group and decreased in the risedronate group. FEA-derived
parameters increased in both groups, but were significantly
higher at 18 months in the teriparatide group. Significant pos-
itive correlations were found between changes from baseline of
PINP at 3, 6 and 18 months with changes in FE strength in the
teriparatide-treated group, but not in the risedronate group.
Conclusions Positive correlations between changes in a bio-
chemical marker of bone formation and improvement of bio-
mechanical properties support the use of PINP as a surrogate
marker of bone strength in teriparatide-treated GIO patients.
Keywords Biochemical markers of bone turnover . bone
strength . finite element analysis . glucocorticoid-induced
osteoporosis . male osteoporosis . teriparatide
Introduction
Biochemical markers of bone turnover (BTMs) are used as
surrogate measures to evaluate the metabolic effect of drugs
on bone turnover, and for predicting fracture risk in patients
with osteoporosis [1, 2]. Changes in BTMs during anti-
osteoporotic therapy depend on the cellular mechanism of
action of the drug, magnitude of change in bone turnover
rate, and route of administration [2]. Studies have found
associations between treatment-related changes in BTMs
with subsequent changes in bone mineral density (BMD),
static and dynamic bone histomorphometric variables, and
fracture outcomes during osteoporosis drug therapy [3–21].
However, these correlations are sometimes weak or non-
significant, and can vary according to the BTMs measured,
methodological limitations — including analytical variabil-
ity — type of patients studied, and skeletal site assessed;
they are also influenced by factors such as age, gender, use
of prior osteoporosis medications and recent fracture [1, 2].
Bone strength, the maximum force a bone can bear, is the
most important determinant of fracture risk and can be
estimated in vivo in humans using finite element analysis
(FEA) based on bone images obtained using quantitative
computed tomography (QCT) [22–25]. Studies have shown
an increase in vertebral strength during bisphosphonate and
teriparatide treatment of postmenopausal women with oste-
oporosis [26–29] and in men with glucocorticoid-induced
osteoporosis (GIO) [30].
The correlations between changes in BTMs and bone
strength induced by pharmacological interventions have
not previously been analysed in detail. Chevalier et al.
[28] briefly reported a positive correlation between changes
in bone strength and changes in the bone formation marker
serum procollagen type I N-terminal propeptide (PINP) in
postmenopausal women with osteoporosis treated with
teriparatide after long-term exposure to bisphosphonates.
However, the relationship between serum markers of bone
turnover and bone strength during treatment with
bisphosphonates and bone forming drugs in men with GIO
has not been investigated before. GIO, the most common
cause of secondary osteoporosis, is characterized by bone
loss and impaired bone quality [31]. Chronic use of gluco-
corticoids (GC) leads to reduced bone formation via inhibi-
tion of differentiation, lifespan and function of osteoblasts
and osteocytes [31–33]. This is reflected in decreased serum
levels of bone formation markers in patients taking GC and,
overall, a reduced bone turnover status in subjects with
long-term GC treatment [34–36].
The aim of this predefined analysis of the EuroGIOPS
trial (clinicaltrials.gov identifier: NCT00503399) was to
examine the relationship between BTMs and bone strength
estimated by high-resolution QCT (HRQCT)-based FEA at
6 and 18 months of therapy with teriparatide or risedronate
in men with GIO. In particular, we determined the correla-
tions between early changes in serum bone turnover markers
with subsequent changes in bone strength under different
loading conditions.
Methods
Study design
This 18-month, randomized, open-label, controlled study
comparing the effects of teriparatide and risedronate in
men with GIO was conducted at 16 centres in Germany,
Greece, Italy, and Spain. The study design and baseline
characteristics of the patients have been reported previously
[30, 37]. Briefly, following a screening phase that lasted up
to 6 weeks, patients attended a baseline visit at which they
were randomized (1:1) to open-label treatment for 18
months with either teriparatide (20 μg once a day as a
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subcutaneous injection) or risedronate (35 mg once weekly
orally as a tablet). Randomization was stratified by previous
bisphosphonate use, and any previous osteoporosis treat-
ment was discontinued during the screening phase before
the baseline visit and for the duration of the study. During
the study, all but one patient concomitantly received 1 g
elemental calcium (as calcium carbonate alone or mixed
with calcium lactogluconate), and 800–1,200 IU vitamin
D/day. After randomization, patients attended clinic visits
at approximately 3, 6, 12, and 18 months. The study was
approved by the responsible institutional review boards at
each centre and was conducted in accordance with the
ethical standards of the Declaration of Helsinki and consis-
tent with good clinical practice.
Participants
The patients enrolled in the study were men aged ≥25 years,
ambulatory, with normal laboratory values for serum calci-
um, alkaline phosphatase, 25-hydroxyvitamin D and para-
thyroid hormone (PTH). They had a lumbar spine (L1−L4),
femoral neck, or total hip BMD T-score of at least 1.5
standard deviations (SDs) below the corresponding normal
young adult men average BMD, and had at least two lumbar
vertebrae without artefacts, fractures, or other abnormalities
that would interfere with dual X-ray absorptiometry (DXA)
or computed tomography (CT) assessments. Patients had
received GC therapy at an average dose of at least
5.0 mg/day of prednisone or its equivalent for a minimum
of 3 consecutive months immediately preceding the screen-
ing visit. Exclusion criteria included unresolved skeletal
diseases other than GIO, presence of a spinal fracture in
both T12 and L1, impaired renal function (creatinine clear-
ance <30 ml/min/1.73 m2), abnormal thyroid function not
corrected by therapy, history of symptomatic nephro- or
urolithiasis in the year prior to randomization, malignant
neoplasms in the 5 years prior to randomization, and any
contraindication to therapy with teriparatide and risedronate.
Patients were also excluded if they had taken intravenous
bisphosphonates within 12 months prior to the screening
visit, or strontium ranelate or fluoride at therapeutic doses
(≥20 mg/day) for more than 3 months in the 2 years prior to
randomization, or for more than a total of 2 years, or at any
dosages within the 6 months prior to randomization. Previ-
ous treatment for any duration with calcitonin, oral
bisphosphonates, or active vitamin D3 analogues that had
been stopped prior to or at the randomization visit was
allowed. All patients provided written informed consent.
Biochemical markers of bone turnover
Serum concentrations of two BTMs were measured at base-
line and at 3, 6 and 18 months of treatment: (1) the bone
formation marker PINP and (2) the bone resorption marker
C-terminal cross-linked telopeptides of type I collagen
(CTx). Fasting blood samples (10 ml) were collected in
the morning, then serum samples were prepared and stored
at −20 °C or lower at the study site for up to 4 months before
being sent to a central laboratory (Covance, Geneva, Swit-
zerland) for storage at −80 °C and processing. All samples
from an individual were assayed in a single analytical batch.
Serum intact PINP was measured by the Intact UniQ RIA
assay (Orion Diagnostica, Espoo, Finland). This assay is not
sensitive to the small molecular weight degradation products
of the pro-peptide (cross-reaction only 1.2 %). The inter-
assay (within day) analytical coefficient of variation (CV)
was less than 3.1–8.2 % over the reference interval. Serum
CTx was measured by the Serum Crosslaps® ELISA (Nor-
dic Bioscience Diagnostics, Herlev, Denmark). The inter-
assay CV was 5.4–11.4 %.
High-resolution quantitative CT and FEA
CT scans were performed at baseline and at 6 and 18 months
of treatment. To optimize image quality serving as the input
data for FE analyses, we used an HRQCT protocol rather
than a standard QCT protocol with thicker slices and lower
plane resolution. All HRQCT assessments performed in this
study have been described elsewhere [30, 37], and are
briefly summarized below.
A thin-slice spiral CT of the 12th thoracic vertebra (T12)
was acquired using a scanner set at 120 kVand 360 mA s. If
T12 was fractured, the HRQCT was performed on an intact
L1 vertebra. Two images were reconstructed. The first one
had a large field of view (FOV), included the patient and
calibration phantom, and was used to calibrate the second
image on which all analyses were carried out. The second
image, with a smaller FOV size of 80 or 96 mm (pixel sizes
of 0.156 or 0.188 mm) depending on the scanner type,
included only the vertebra. In this latter image, the com-
plete vertebral body was segmented using a semi-
automatic algorithm. A template vertebra was registered
in 3D to each scan and subsequently adapted to the
individual anatomy by an active contour.
HRQCT-based FEA was used to estimate the effects
of treatment on bone strength and stiffness at T12
using the technique described by Graeff et al. [38].
Digital finite element models were generated for each
patient from the segmented HRQCT images at an iso-
metric resolution of 1.3 mm. The superior and inferior
endplates were embedded in a thin layer of polymethyl-
methacrylate (PMMA) and the mineral density of each
voxel/element was converted to bone volume fraction
(BV/TV) with a calibration equation assuming a homo-
geneous tissue density. The bone tissue material behav-
iour was elastoplastic with damage; that is, irreversible
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strains develop and elastic modulus degrades with post-
yield loading history. The model generation procedure
and bone material properties have been described in
detail by Chevalier et al. [39]. To account for a broad
spectrum of physiological loading, the FEAs of each
vertebral body included axial compression, anterior
bending and axial torsion. The structural output vari-
ables computed by the FEAs were axial stiffness
(kN/mm) and maximal load (kN) for axial compres-
sion, and angular stiffness (kN mm/rad) and maximal
torque (kN mm) for anterior bending and axial tor-
sion. A normalized strength in axial compression
(N/mm2=MPa) was also calculated as strength divided by
the central cross-sectional area of the entire vertebral body.
All personnel in the radiology departments of the study
sites were blinded to treatment assignment to reduce any
potential bias from the open-label study design. Likewise,
all scans were assessed centrally by radiology readers and
engineers blinded to treatment assignment.
Statistical analysis
This was a pre-planned analysis of the EuroGIOPs clinical
trial. All randomized patients who received at least one dose
of study medication were included in the analyses. A mixed-
model of repeated measures (MMRM) was used to analyse
between-group differences and within- group changes by
modelling the changes from baseline in BTM and FEA
parameters. The model included terms for baseline value,
treatment, visit, interaction between treatment and visit, age,
baseline PINP, fracture within 12 months prior to study
(yes/no), duration of bisphosphonate use, baseline GC dose,
and cumulative GC doses before and during the study (fixed
effects). Patients nested within treatment were included as
random effects. Within the treatment groups, adjusted
means obtained after controlling for the covariates (least
square means [LS means]) with standard errors were derived
at each of the follow-up visits. For differences between
treatment groups, p values were derived and are presented
in the results. The p values for the within group changes
from baseline were derived and are indicated in the results
when p<0.05.
Within each treatment group, Spearman correlation
coefficients with their associated two-sided p values,
and residual mean square errors derived from linear
regressions were both calculated for the absolute
changes from baseline in BTMs at 3, 6 and 18 months
with the changes from baseline in HRQCT-based FEA
variables at 18 months. Scatter plots are presented and
the regression lines are drawn to visualize relationships.
The level of statistical significance was set to 5% and
no multiplicity adjustments were performed. Data were
analysed using SAS software© version 9.2.
Results
Patient disposition and baseline characteristics
Of the 174 male patients enrolled in the study, 92
were randomly assigned to receive treatment with
teriparatide (n=45) or risedronate (n=47). Seventy-
seven subjects (83.6 %) completed the 18-month treat-
ment duration (teriparatide, n=38; risedronate, n=39),
and 28 patients in each treatment group had HRQCT
valid measurements.
The baseline demographic and clinical characteristics
of the patients in the two treatment groups were similar
and are reported in full elsewhere [30]. Mean age was
56.3 years (range 25–82 years) and 39.1% had at least
one fracture prior to the study. Of the 92 patients, 31
(33.7 %) had a previous osteoporosis therapy, most
commonly bisphosphonates (30 patients). All patients
were on GC therapy prior to the study, mainly for
musculoskeletal and connective tissue disorders
(32.7 %), respiratory, thoracic and mediastinal disorders
(23.6 %), or for gastrointestinal disorders (15.5 %). The
median daily GC dose at baseline was 8.8 mg
(interquartile range [IQR] 5.0–15.0 mg/day) and the
median duration of prior GC therapy was 6.4 years
(IQR 2.4–13.0 years).
Effects of treatment on bone turnover markers
MMRM analysis revealed that the adjusted mean changes
from baseline in PINP and CTx at 3, 6 and 18 months of
therapy in the teriparatide and risedronate groups (Fig. 1)
show significant differences between treatments at each of
these time points (p<0.001) with the exception of CTx at
month 18 (p=0.105).
Changes in FEA variables during treatment
Table 1 summarizes the absolute values of the finite
element strength variables under the different loading
modes (anterior bending, axial compression, and axial
torsion) and the results for axial strength after normal-
ization by vertebral body size at baseline and at 6 and
18 months of treatment in the teriparatide and
risedronate groups. There were increases from baseline
during treatment in both groups. MMRM analysis
showed that the increases in finite element strength
and normalized axial compression strength at 18 months
were significantly higher in the teriparatide group com-
pared with the risedronate group (p≤ 0.05). The
between-treatment differences were not statistically sig-
nificant at 6 months (Table 1). Similar results were
observed for stiffness (data not shown).
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Correlations between changes in bone turnover markers
and changes in FEA variables
Table 2 presents the Spearman correlation coefficients be-
tween the absolute changes from baseline of PINP at 3, 6
and 18 months and the absolute changes from baseline in
FEA parameters at 18 months of therapy in the teriparatide
and risedronate groups. Significant positive correlations be-
tween the change in PINP at 3, 6 and 18 months with the
changes in finite element strength and stiffness in all loading
modes at 18 months (anterior bending, axial compression,
and axial torsion) and in the change in normalized axial
compression strength were observed in the teriparatide
group (r=0.422 to r=0.563). Based on PINP measure-
ments at the three time points, the changes in anterior
bending strength associated with teriparatide treatment
could be estimated with residual mean square errors
between 37.0 and 42.0 kN mm. Similarly, the changes
in axial compression and axial torsion strengths could
be estimated with residual mean square errors between
2.1 and 2.3 kN, and 17.9 and 20.7 kN mm, respective-
ly. There were no significant correlations in the
risedronate-treated group (Table 2). Figure 2 shows the
absolute change correlations of PINP at 3, 6 and
18 months with finite element strength variables at
18 months in the teriparatide and risedronate groups.
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Fig. 1 Mean (SE) changes
from baseline for the bone
markers a PINP and b CTx at 3,
6 and 18 months in the
teriparatide and risedronate
treatment groups. *p<0.001 for
between-treatment
comparisons, +p<0.05 for
change from baseline within
groups. Mixed model repeated
measures analysis of changes
from baseline including fixed
effects for treatment, visit and
the interaction between
treatment and visit, and random
effects for patients nested
within treatment, plus the
following covariates: age,
baseline PINP, fracture <12
months before study, duration
of prior bisphosphonate use,
screening GC dose, and
cumulative GC dose prior to
and during study. LS least
squares, CTx type I collagen
degradation fragments, PINP
aminoterminal propeptide of
type I procollagen, SE standard
error
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There were few significant correlations between absolute
changes in serum CTx and absolute changes in FE strength
variables in either treatment group (Table 2).
Discussion
Our study is the first to examine the relationship between
changes in serum bone turnover markers and changes in FE-
computed vertebral strength in men with GIO during oste-
oporosis drug therapy. We found a strong correlation be-
tween the increase in PINP, a bone formation marker, at 6
months and the subsequent increase in vertebral strength for
all tested loading modes in the teriparatide-treated group,
but not in the risedronate-treated group. Moreover, the anal-
ysis of the residual mean square errors indicates that the
estimations of the changes in strength indices based on
PINP changes in the teriparatide group were meaningful.
This supports that PINP could be used as a surrogate marker
of biomechanical indices in GIO patients treated with
teriparatide, given the well-known correlation between FE-
derived bone strength analysis and fractures [25, 40].
Our results complement previous findings in studies that
have analysed the correlations between the bone marker
response to teriparatide and other bone endpoints, such as
BMD [4, 9, 13, 16, 18, 21, 41], histomorphometric variables
[10, 42, 43] and spine strength [44] in patients with osteo-
porosis. In general, the strength of the correlations we have
observed with FE analysis is numerically higher than with
other bone parameters reported in teriparatide-treated subjects.
Chevalier et al. [28] previously reported a statistically
significant correlation between the area under the curve
PINP concentrations from baseline to 12 months and the
change in FEA-estimated vertebral bone strength in 171
postmenopausal women with osteoporosis treated with
teriparatide in the OPTAMISE study. Based on the square
of the correlations, they showed that 19 % of the variation in
the percentage change in maximal load can be explained by
PINP changes after 12 months of treatment with teriparatide,
while our equivalent analysis yields a maximum of 31% of
the variation in the percentage of the axial compression
strength after 18 months being explained by the PINP early
changes. Besides the timing of the assessments, the two
studies differ in patient population characteristics (all wom-
en in the OPTAMISE study received bisphosphonates prior
to teriparatide for at least 2 years), and in the CT methods
applied to evaluate the FE-derived strength; these differ-
ences may explain the differential results between the two
studies. Additionally, the assay used in our study measures
intact PINP, while investigators in the OPTAMISE trial used
Table 1 Finite element strength in the different loading modes (anterior bending, axial compression, axial torsion) and normalized axial
compression strength for the teriparatide and risedronate treatment groups
Variable Time (months) Teriparatide Risedronate p value a
n Mean (SD) n Mean (SD)
Finite element strength
Anterior bending (kN mm) Baseline 36 94.7 (41.8) 36 96.2 (42.3) –
6 25 121.3 (49.9) 32 113.5 (46.0) 0.661
18 29 140.2 (58.8)b 31 112.8 (40.8) 0.012
Axial compression (kN) Baseline 36 5.07 (2.33) 37 4.90 (2.28) –
6 25 6.21 (2.87) 33 5.81 (2.23) 0.547
18 31 7.08 (3.48)b 31 5.95 (2.2) 0.015
Axial torsion (kN mm) Baseline 36 48.4 (22.1) 37 48.6 (21.2) –
6 25 62.4 (26.3) 33 57.9 (20.9) 0.548
18 31 71.0 (31.8)b 31 58.2 (19.2) 0.005
Normalized axial compression strength (N/mm2)
Baseline 36 4.50 (2.20) 37 4.41 (2.16) –
6 25 5.32 (2.71) 33 5.25 (2.18) 0.677
18 31 6.13 (3.29)b 31 5.38 (2.08) 0.021
a p value for between group comparison
b Change from baseline within groups (p<0.05) from a mixed model repeated-measures analysis of changes from baseline including fixed effects
for treatment, visit and the interaction between treatment and visit, and random effects for patients nested within treatment, plus the following
covariates: age, baseline PINP, fracture <12 months before study, duration of prior bisphosphonate use, screening GC dose, and cumulative GC
dose prior to and during study. MMRM sample sizes for changes from baseline to 6 months (n=23), and to 18 months (n=28) for Teriparatide; and
baseline to 6 months (n=28), and to 18 months (n=28) for Risedronate
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a different method that measures total PINP (i.e., including
monomer and trimer).
Recently, there has been growing interest in the potential
value of monitoring bone marker changes and bone strength
to evaluate treatment response and fracture outcomes. Pre-
vious studies have shown an association between changes in
bone turnover markers and fracture incidence/risk in post-
menopausal women treated with antiresorptive therapies,
including alendronate [7], risedronate [19, 45] and raloxi-
fene [5, 6, 8], but not with strontium ranelate [46] or
zoledronic acid [15]. Researchers from the EUROFORS
trial reported the lack of a significant relationship between
changes in biochemical markers and fracture risk in post-
menopausal women treated with teriparatide [18]. However,
these results should be interpreted with caution given the
low number of subjects with incident fractures during the
course of the study, and the lack of power to detect any
potential correlations. Further studies are needed to define
the role of biochemical markers as predictors of fracture
outcomes during teriparatide therapy.
Studies have shown that, in general, there is an associa-
tion between bone strength assessed by different types of
QCT methods and fractures in men and women with osteo-
porosis [47–51]. Specifically, vertebral fractures are strong-
ly associated with vertebral strength estimated using FE
models in men older than 65 years [51] and in postmeno-
pausal women [47]. In the baseline analysis of the
EuroGIOPS study in men with GIO, all HRQCT-based
Table 2 Spearman correlation coefficients (r values) between the absolute changes in serum PINP and CTx at 3, 6, and 18 months and the absolute
changes in FEA parameters at 18 months by treatment group
Time
(months)
Finite element strength Finite element stiffness Normalized
axial
compressionAnterior
bending
Axial
compression
Axial
torsion
Anterior
bending
Axial
compression
Axial
torsion
PINP
Teriparatide Δ3 0.422* 0.516** 0.496* 0.397 0.525* 0.402 0.539**
(n=23) (n=24) (n=24) (n=24) (n=24) (n=24) (n=24)
Δ6 0.486* 0.560*** 0.544*** 0.477* 0.550* 0.472* 0.563***
(n=23) (n=25) (n=25) (n=25) (n=25) (n=25) (n=25)
Δ18 0.546* 0.522* 0.455* 0.413 0.517* 0.403 0.553**
(n=19) (n=21) (n=21) (n=21) (n=21) (n=21) (n=21)
Risedronate Δ3 −0.033 0.043 0.031 −0.093 0.021 −0.084 0.046
(n=27) (n=27) (n=27) (n=27) (n=27) (n=27) (n=27)
Δ6 −0.023 0.006 0.028 −0.048 −0.005 −0.046 0.001
(n=29) (n=29) (n=29) (n=29) (n=29) (n=29) (n=29)
Δ18 −0.141 −0.213 −0.239 −0.316 −0.297 −0.358 −0.195
(n=23) (n=23) (n=23) (n=23) (n=23) (n=23) (n=23)
CTx
Teriparatide Δ3 0.353 0.380 0.350 0.321 0.383* 0.331 0.399*
(n=26) (n=27) (n=27) (n=27) (n=27) (n=27) (n=27)
Δ6 0.382 0.380* 0.339 0.254 0.379* 0.284 0.412*
(n=26) (n=28) (n=28) (n=28) (n=28) (n=28) (n=28)
Δ18 0.381 0.382 0.326 0.217 0.367 0.236 0.424
(n=18) (n=20) (n=20) (n=20) (n=20) (n=20) (n=20)
Risedronate Δ3 −0.099 −0.052 −0.027 −0.096 −0.062 −0.103 −0.050
(n=29) (n=29) (n=29) (n=29) (n=29) (n=29) (n=29)
Δ6 −0.070 −0.015 −0.003 0.006 0.003 0.005 −0.029
(n=30) (n=30) (n=30) (n=30) (n=30) (n=30) (n=30)
Δ18 −0.118 −0.225 −0.202 −0.198 −0.248 −0.220 −0.214
(n=28) (n=28) (n=28) (n=28) (n=28) (n=28) (n=28)
Δ3, Δ6 and Δ18 respectively represent change from baseline in serum PINP/CTx at 3, 6 and 18 months versus changes from baseline in FEA
parameters at 18 months.
FEA finite element analysis, PINP aminoterminal propeptide of type I procollagen, CTx cross-linked C-telopeptide of type I collagen
*p<0.05; **p≤0.01; ***p≤0.005
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FEA estimates of vertebral bone strength were significantly
correlated with vertebral fracture status at baseline [37].
Additionally, trabecular BMD measured using QCT or
HRQCT, but not BMD by DXA, was associated with
vertebral fracture status [37]. Vertebral fractures in men
have also been associated with bone strength estimated
by QCT-based FEA at the hip [48] and at the distal
radius and tibia [52].
A novel approach in our study was the analysis using
three loading modes for vertebral bone strength, inclu-
ding axial torsion, which has not been examined before.
We also accounted for bone size by normalizing bone
strength with cross-sectional area of the entire vertebral
body. All these measures of vertebral bone strength
increased to a greater extent in the teriparatide group
compared with the risedronate group, with no major
differences depending on the loading mode, although
the axial compression strength showed higher correla-
tions with changes in PINP.
The observed increase in strength in axial compres-
sion in our study in the teriparatide-treated subjects
(26.0 %) and in the risedronate group (4.2 %) [30]
yielded similar results compared to previous studies of
the effects of teriparatide and alendronate treatment on
vertebral strength in postmenopausal women with oste-
oporosis, where Keaveny et al. [26] have shown in-
creases in FE-assessed vertebral strength of 21 % with
teriparatide versus 4 % with alendronate at 18 months,
and Graeff et al. [27] have reported a 28 % increase in
compressive and bending strength at 2 years of
teriparatide treatment.
Similarly, the observed increases in PINP and CTx in
the teriparatide-treated group are consistent with pre-
vious studies showing an increase in bone turnover
markers during teriparatide therapy in men and women
with osteoporosis [13, 18, 36, 42, 53–57]. Specifically,
the maximum change from baseline in PINP and CTx
was seen at 6 months; this was followed by a decrease
in bone marker levels but, at 18 months, the level of
PINP remained increased relative to baseline. This pat-
tern of change in serum PINP levels has been observed
in other studies of teriparatide-treated patients with GIO
[36, 56], in postmenopausal women with osteoporosis
[18, 42], and in men with osteoporosis [13]. Moreover,
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Fig. 2 Scatter plots for the absolute change from baseline of PINP at 3, 6
and 18months against the absolute change in finite element strength at 18
months of therapy with teriparatide (filled circles) or risedronate (open
circles) for the three loading modes: a anterior bending, b axial compres-
sion, and c axial torsion. Each figure shows the trend line for correlations
with p<0.05 for teriparatide. r Spearman rank correlation coefficient
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the absolute change from baseline in PINP at every time point
in our study was well above the least significant change
determined previously (10 μg/l) and used to monitor the early
response to teriparatide treatment [21, 55].
Although our study has several important strengths, such
as the prospective design in a group of patients with osteo-
porosis who have scarcely been evaluated in clinical trials,
the application for the first time of novel HRQCT-based FE
analysis in men with GIO, and a MMRM analysis adjusted
for factors such as age, prior fracture, duration of prior
bisphosphonate use and GC dose, it also has some limita-
tions. These include that the analysis was restricted to only
one vertebra (T12), but vertebral strength may vary along
the spine. Second, the FE analysis assumes that bone tissue
properties are constant for all patients during longitudinal
treatment. However, since the patients involved in the study
were GC users for several years, we do not expect a change
in the local BMD–strength relationship in the course of the
study. A hypothetical shift of the local BMD–strength rela-
tionship due to GC therapy throughout the study would
influence neither the trends of the FE analysis nor the
reported correlations. Other limitations of the study are that
the duration of treatment was for 18 months only and the
limited sample size. Longer treatment may offer even more
pronounced advantages for both drugs. Although we only
measured serum levels of PINP and CTx, these have recent-
ly been recommended as the reference markers of bone
turnover to be used in clinical studies [1].
In conclusion, teriparatide at 20 μg/day demonstrated
superior efficacy compared to risedronate 35 mg/week in
the effects on biomechanical indices estimated by HRQCT-
based FEA at the 12th thoracic vertebra in male patients
with GIO. The changes from baseline in PINP revealed
significant positive correlations with the changes in verte-
bral strength in all the loading modes at 18 months in the
teriparatide group only. Changes in serum CTx showed
fewer correlations. Serial spine QCT involves exposure to
significant levels of radiation and considerable costs, which
will limit its widespread use in normal clinical practice as an
indicator of vertebral bone strength. Because bone strength
estimated using this method was correlated significantly
with serum levels of the bone formation marker PINP during
teriparatide treatment, this suggests that monitoring of PINP
may be clinically useful as a surrogate marker of biome-
chanical properties in GIO patients treated with teriparatide,
but further studies with larger study populations and corre-
lations with fracture outcomes are needed.
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